CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Apr. 02, 2022	Jan. 01, 2022
Current assets:
Cash and cash equivalents	$ 17,439	$ 30,490
Patient accounts receivable	240,895	218,917
Receivables under insured programs	6,900	6,373
Prepaid expenses	15,330	14,233
Other current assets	5,649	9,202
Total current assets	286,213	279,215
Property and equipment, net	29,491	31,374
Operating lease right of use assets	51,289	51,992
Goodwill	1,837,437	1,835,580
Intangible assets, net	102,196	102,851
Receivables under insured programs	27,615	25,530
Other long-term assets	41,788	7,829
Total assets	2,376,029	2,334,371
Current liabilities:
Accounts payable and other accrued liabilities	57,309	52,624
Accrued payroll and employee benefits	53,019	54,565
Current portion of insurance reserves - insured programs	6,900	6,373
Current portion of insurance reserves	14,532	13,466
Securitization obligations	140,000	120,000
Current portion of long-term obligations	8,600	8,600
Current portion of operating lease liabilities	13,685	13,534
Current portion of deferred payroll taxes	25,523	25,523
Other current liabilities	48,222	50,146
Total current liabilities	367,790	344,831
Long-term obligations, less current portion	1,225,428	1,226,517
Long-term insurance reserves - insured programs	27,615	25,530
Long-term insurance reserves	37,892	35,122
Operating lease liabilities, less current portion	43,651	44,682
Deferred income taxes	4,460	3,046
Other long-term liabilities	1,093	16,692
Total liabilities	1,707,929	1,696,420
Commitments and contingencies (Note 10)
Deferred restricted stock units	2,135	2,135
Stockholders’ equity:
Preferred stock, $0.01 par value as of April 2, 2022 and no par value as of January 2, 2021, 5,000,000 shares authorized; none issued or outstanding
Common stock, $0.01 par value, 1,000,000,000 shares authorized; 184,732,268 and 184,732,268 issued and outstanding, respectively	1,847	1,847
Additional paid-in capital	1,213,460	1,208,645
Accumulated deficit	(549,342)	(574,676)
Total stockholders’ equity	665,965	635,816
Total liabilities, deferred restricted stock units, and stockholders’ equity	$ 2,376,029	$ 2,334,371